Table 1.
Characteristics of selected cohort of patients from the National Cancer Database (NCDB)* with stage III or IV (M0) hypopharyngeal squamous cell carcinoma (SCC) diagnosed between 2004 and 2015.
| Characteristics† | CRT | S+Adj | Total | P-Value‡ | |||
|---|---|---|---|---|---|---|---|
|
| |||||||
| N = 5,349 | N = 706 | N = 6,055 | |||||
| Age | 60 | (54–68) | 60 | (54–66) | 60 | (54–68) | 0.030 |
| Sex | 0.35 | ||||||
| Female | 1,002 | (18.7%) | 122 | (17.3%) | 1,124 | (18.6%) | |
| Male | 4,347 | (81.3%) | 584 | (82.7%) | 4,931 | (81.4%) | |
| Race/Ethnicity§ | 0.50 | ||||||
| NHW | 3,835 | (75.6%) | 513 | (77.3%) | 4,348 | (75.8%) | |
| NHB | 847 | (16.7%) | 109 | (16.4%) | 956 | (16.7%) | |
| NHO | 142 | (2.8%) | 18 | (2.7%) | 160 | (2.8%) | |
| Hispanic | 250 | (4.9%) | 24 | (3.6%) | 274 | (4.8%) | |
| Distance to Hospital, miles | 9 | (3.9–21.9) | 15.3 | (5.6–45.5) | 9.5 | (4.0–23.9) | <0.001 |
| Insurance | 0.15 | ||||||
| Not Insured | 382 | (7.4%) | 40 | (5.9%) | 422 | (7.2%) | |
| Private Insurance | 1,845 | (35.7%) | 252 | (37.0%) | 2,097 | (35.8%) | |
| Medicaid | 846 | (16.4%) | 132 | (19.4%) | 978 | (16.7%) | |
| Medicare | 1,947 | (37.6%) | 239 | (35.1%) | 2,186 | (37.3%) | |
| Other Government | 154 | (3.0%) | 18 | (2.6%) | 172 | (2.9%) | |
| Charlson-Deyo Score | 0.001 | ||||||
| 0 | 4,183 | (78.2%) | 510 | (72.2%) | 4,693 | (77.5%) | |
| 1 | 871 | (16.3%) | 157 | (22.2%) | 1,02 8 | (17.0%) | |
| 2 | 217 | (4.1%) | 30 | (4.2%) | 247 | (4.1%) | |
| >=3 | 78 | (1.5%) | 9 | (1.3%) | 87 | (1.4%) | |
| Primary Site‖ | 0.010 | ||||||
| Piriform Sinus | 2,754 | (51.5%) | 413 | (58.5%) | 3,167 | (52.3%) | |
| Post-Cricoid Region | 92 | (1.7%) | 10 | (1.4%) | 102 | (1.7%) | |
| AE Fold | 328 | (6.1%) | 29 | (4.1%) | 357 | (5.9%) | |
| Posterior Wall | 301 | (5.6%) | 31 | (4.4%) | 332 | (5.5%) | |
| OL | 246 | (4.6%) | 34 | (4.8%) | 280 | (4.6%) | |
| NOS | 1,628 | (30.4%) | 189 | (26.8%) | 1,817 | (30.0%) | |
| HPV¶ | 0.90 | ||||||
| HPV− | 711 | (74.0%) | 108 | (74.5%) | 819 | (74.1%) | |
| HPV+ | 250 | (26.0%) | 37 | (25.5%) | 287 | (25.9%) | |
| Grade# | 0.002 | ||||||
| I | 194 | (4.9%) | 15 | (2.2%) | 209 | (4.5%) | |
| II | 2,189 | (55.7%) | 368 | (54.7%) | 2,557 | (55.6%) | |
| III | 1,510 | (38.4%) | 278 | (41.3%) | 1,788 | (38.9%) | |
| IV | 35 | (0.9%) | 12 | (1.8%) | 47 | (1.0%) | |
| T Stage | <0.001 | ||||||
| T1 | 536 | (10.0%) | 44 | (6.2%) | 580 | (9.6%) | |
| T2 | 1,627 | (30.4%) | 101 | (14.3%) | 1,728 | (28.5%) | |
| T3 | 1,741 | (32.5%) | 186 | (26.3%) | 1,927 | (31.8%) | |
| T4 | 1,445 | (27.0%) | 375 | (53.1%) | 1,820 | (30.1%) | |
| N Stage | <0.001 | ||||||
| N0 | 749 | (14.0%) | 113 | (16.0%) | 862 | (14.2%) | |
| N1 | 1,104 | (20.6%) | 122 | (17.3%) | 1,226 | (20.2%) | |
| N2 | 3,076 | (57.5%) | 466 | (66.0%) | 3,542 | (58.5%) | |
| N3 | 420 | (7.9%) | 5 | (0.7%) | 425 | (7.0%) | |
| Summary Stage | <0.001 | ||||||
| III | 1,364 | (25.5%) | 108 | (15.3%) | 1,472 | (24.3%) | |
| IVA | 3,064 | (57.3%) | 55 | (7.8%) | 3,11 9 | (51.5%) | |
| IVB | 834 | (15.6%) | 543 | (76.9%) | 1,377 | (22.7%) | |
| IVNOS | 87 | (1.6%) | 0 | (0.0%) | 87 | (1.4%) | |
| Survival Time, months | 22.0 5 | (10.7–48.5) | 27. 3 | (13.5–55.7) | 22.7 | (11.0–49.0) | <0.001 |
Subjects were included in the chemotherapy and radiation group (CRT) if they had received primary radiation and chemotherapy. Subjects were included in the surgery with adjuvant therapy group (S+Adj) if they received primary surgery with either adjuvant radiation or adjuvant radiation and chemotherapy.
Plus-minus values are mean ± standard deviation for normally distributed continuous variables. Values for non-normal continuous variables are reported as median (interquartile range). Frequencies are reported as number (proportion of overall group within column).
The continuous variables all had non-normal distribution and were assessed with Kruskall-Wallis test. Chi-Square tests were used to assess categorical variables.
Abbreviations: NHW—Non-Hispanic ethnicity, white race; NHB—Non-Hispanic ethnicity, black race; NHO—Non-Hispanic ethnicity, other race; H—Hispanic ethnicity, all races
Abbreviations: AE Fold—Aryepiglottic fold; OL—Overlapping lesion of the hypopharynx; NOS—Hypopharynx, not otherwise specified
HPV Status was only available for the 1,123 subjects those diagnosed between 2010–2015.
Grade was missing for 1,298 subjects (34 of these were in the S+Adj group and 1,264 were in the CRT group).